Research
Hormonal
Elevated ceramide levels contribute to the expression of inflammatory adipokines MCP-1 and PAI-1, while TNF-alpha acts upstream of ceramide biosynthesis.
High ceramide levels drive inflammation markers like MCP-1 and PAI-1 in fat tissue, while TNF-alpha triggers ceramide production.
GoodSupportsHIGH confidence
expression of MCP-1 mRNA was significantly reduced in adipose tissues of myriocin-treated DIO mice... PAI-1 mRNA expression was dramatically and significantly reduced in adipose tissues of myriocin-treated obese mice... plasma ceramide levels were significantly reduced in obese (ob/ob) mice that lack both TNF receptors... confirming that TNF-alpha is upstream of a pathway that contributes to elevated ceramide biosynthesis.
Why this rating
Supported by multiple lines of evidence including gene expression and receptor knockout studies.
Source
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome
Guang Yang et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009
DOI 10.1152/ajpendo.91014.2008
mechanism_onlyCited 294×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Inhibition of de novo ceramide biosynthesis using myriocin reduces body weight and fat mass in obese mice by increasing energy expenditure and metabolic rate, independent of food intake.Good
- Inhibition of ceramide biosynthesis improves glucose tolerance and insulin sensitivity in obese mice by restoring insulin signaling (Akt phosphorylation) in the liver and muscle.Good
- Inhibition of ceramide biosynthesis improves hepatic steatosis (fatty liver) in obese mice, associated with reduced hepatic SOCS-3 expression.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →